Experience. Commitment. Results.
American National Bankshares Inc. (Nasdaq: AMNB), relating to its proposed sale to Atlantic Union Bankshares Corp. Under the terms of the agreement, AMNB shareholders will receive 1.35 shares of Atlantic per share they own.
New Relic, Inc. (NYSE: NEWR), relating to its proposed sale to Francisco Partners. Under the terms of the agreement, NEWR shareholders will receive $87.00 in cash per share they own.
Denbury, Inc. (NYSE: DEN), relating to its proposed sale to Exxon Mobil Corp. Under the terms of the agreement, DEN shareholders are expected to receive $89.45 in cash per share they own.
Frequency Therapeutics, Inc. (Nasdaq: FREQ), relating to its proposed merger with Korro Bio, Inc. Under the terms of the agreement, FREQ shareholders are expected to own approximately 8% of the combined company
eMagin Corp. (NYSE: EMAN), relating to its proposed sale to Samsung Display Co., Ltd. Under the terms of the agreement, EMAN shareholders are expected to receive $2.08 in cash per share they own.
Chase Corp. (NYSE: CCF), relating to its proposed sale to an affiliate of investment funds managed by KKR. Under the terms of the agreement, CCF shareholders are expected to receive $127.50 in cash per share they own.
Heritage-Crystal Clean, Inc. (Nasdaq: HCCI), relating to its proposed sale to an affiliate of J.F. Lehman & Co. Under the terms of the agreement, HCCI shareholders are expected to receive $45.50 in cash per share they own.
Neoleukin Therapeutics, Inc. (Nasdaq: NLTX), relating to its proposed merger with Neurogene Inc. Under the terms of the agreement, NLTX shareholders are expected to own approximately 16% of the combined company.
Sculptor Capital Management Inc. (NYSE: SCU), relating to its proposed sale to Rithm Capital Corp. Under the terms of the agreement, Class A SCU shareholders are expected to receive $11.15 in cash per share they own.
Pardes Biosciences, Inc. (Nasdaq: PRDS), relating to its proposed sale to MediPacific, Inc. Under the terms of the agreement, PRDS shareholders are expected to receive at least $2.02 plus an additional cash amount of at most $0.17 in cash per share they own, as well as one non-tradeable CVR.